Cervical-cancer screening beyond the year 2000

Lancet Oncology

Volumn 2, Issue 1, 2001, Pages 27-32

  Ferenczy, Alex ^a   Franco, Eduardo ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL SEPARATION; COMPUTER ASSISTED DIAGNOSIS; DNA PROBE; FEMALE; GENETICS; HUMAN; MASS SCREENING; METHODOLOGY; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

CELL SEPARATION; DIAGNOSIS, COMPUTER-ASSISTED; DNA PROBES, HPV; FEMALE; HUMANS; MASS SCREENING; UTERINE CERVICAL NEOPLASMS;

EID: 0035240660     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00192-3     Document Type: Review

References (15)

1. Evidence Report/Technology Abstract: number 5,Evaluation of Cervical Cytology (AHCPR Publication No 00-E010), Rockville, MD. Internet citation: www.ahcpr.gov/clinic/index.html 1#evidence.
2. Fahey M.T., Irwig L., Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 141:1995;680-689.
3. Austin R.M., Ramzey I. Increased detection of epithelial cell abnormalities by liquid-based gynecologic cytology preparations: a review of accumulated data. Acta Cytol. 42:1998;178-184.
4. Bishop J.W., Bigner S.H., Colgan T.J., et al. Multicenter masked evaluation of AutoCyte PREP thin layers with matched conventional smear including initial biopsy results. Acta Cytol. 42:1998;189-197.
5. Diaz-Rosario L.A., Kabawat S.E. Performance of a fluid-based, thin-layer Papanicolaou smear method in the clinical setting of an independent laboratory and an outpatient screening population in New England. Arch Pathol Lab Med. 123:1999;817-821.
6. Vassilakos P., Saurel J., Rondez R. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European Laboratories. Acta Cytol. 43:1999;65-68.
7. Wilbur D.C., Prey M.U., Miller W.M., Pawlick G.F., Colgan T.J. The AutoPap System for primary screening in cervical cytology; comparing results of a prospective, intended-use study with routine manual practice. Acta Cytol. 42:1998;214-220.
8. Manos M.M., Kinney W.K., Hurley L.B., et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 281:1999;1605-1610.
9. Cuzick J., Beverley E., Ho L., et al. HPV testing in primary screening of older women. Br J Cancer. 81:1999;554-558.
10. Schiffman M., Herrero R., Hildesheim A., et al. HPV DNA testing in cervical cancer screening. JAMA. 283:2000;87-93.
11. Rozendaal L., Walboomers J.M., van der Linden J.C., et al. PCR-based high-risk HPV test in cervical cancer screening gives objective assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 68:1996;766-769.
12. Walboomers J.M., Jacobs M.V., Manos M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:1999;12-19.
13. Wright T.C., Denny L., Kuhn L., Pollack A., Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA. 283:2000;81-86.
14. Lytwyn A., Gafni A., Sellors J.W., et al. Economic evaluation of hybrid capture human papillomavirus testing in women with low-grade Papanicolaou smear abnormalities. J Lower Genit Tract Dis. 2:1998;213-220.
15. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 80:1999;827-841.